Balance Sheet
Cash Flow Statement
AcquisitionsAmortization of Deferred ChargesAsset Writedowns and ImpairmentCapital ExpendituresCash from Discontinued OperationsCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Pediatrix Medical (MD) Free Cash Flow (2016 - 2025)

Pediatrix Medical (MD) has disclosed Free Cash Flow for 17 consecutive years, with $122.7 million as the latest value for Q4 2025.

  • On a quarterly basis, Free Cash Flow fell 6.63% to $122.7 million in Q4 2025 year-over-year; TTM through Dec 2025 was $269.6 million, a 38.11% increase, with the full-year FY2025 number at $269.6 million, up 38.11% from a year prior.
  • Free Cash Flow was $122.7 million for Q4 2025 at Pediatrix Medical, down from $135.1 million in the prior quarter.
  • In the past five years, Free Cash Flow ranged from a high of $135.1 million in Q3 2025 to a low of -$128.0 million in Q1 2024.
  • A 5-year average of $44.5 million and a median of $81.6 million in 2022 define the central range for Free Cash Flow.
  • Biggest YoY gain for Free Cash Flow was 350.71% in 2021; the steepest drop was 81.07% in 2021.
  • Pediatrix Medical's Free Cash Flow stood at $108.0 million in 2021, then increased by 22.29% to $132.1 million in 2022, then crashed by 31.38% to $90.7 million in 2023, then skyrocketed by 44.9% to $131.4 million in 2024, then decreased by 6.63% to $122.7 million in 2025.
  • Per Business Quant, the three most recent readings for MD's Free Cash Flow are $122.7 million (Q4 2025), $135.1 million (Q3 2025), and $132.7 million (Q2 2025).